ES2063574T3 - Metodo de tratamiento mejorado para el cancer. - Google Patents

Metodo de tratamiento mejorado para el cancer.

Info

Publication number
ES2063574T3
ES2063574T3 ES92901177T ES92901177T ES2063574T3 ES 2063574 T3 ES2063574 T3 ES 2063574T3 ES 92901177 T ES92901177 T ES 92901177T ES 92901177 T ES92901177 T ES 92901177T ES 2063574 T3 ES2063574 T3 ES 2063574T3
Authority
ES
Spain
Prior art keywords
cancer cells
animal
cancer
chemotherapeutical agent
treatment method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92901177T
Other languages
English (en)
Inventor
Lorne J Brandes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manitoba
Original Assignee
University of Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manitoba filed Critical University of Manitoba
Application granted granted Critical
Publication of ES2063574T3 publication Critical patent/ES2063574T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

EL TRATAMIENTO QUIMIOTERAPEUTICO IN VIVO DE LAS CELULAS CANCEROSAS EN UN ANIMAL VIVO, ES MEJORADO ADMINISTRANDO PRIMERAMENTE AL ANIMAL UN ANTAGONISTA ESPECIFICO PARA LA HISTAMINA INTRACELULAR EN UNA CANTIDAD SUFICIENTE PARA INHIBIR EL ENLACE DE LA HISTAMINA INTRACELULAR EN LAS CELULAS NORMALES. SE OBTIENE UN EFECTO TOXICO AUMENTADO SOBRE LAS CELULAS CANCEROSAS A PARTIR DEL AGENTE QUIMIOTERAPEUTICO MIENTRAS ES INHIBIDO CUALQUIER EFECTO PERJUDICIAL DEL AGENTE QUIMIOTERAPEUTICO SOBRE LAS CELULAS NORMALES. ADEMAS, LA ADMINISTRACION CONTINUA A LARGO PLAZO DEL ANTAGONISTA A CONTINUACION DE LA ADMINISTRACION DEL AGENTE QUIMIOTERAPEUTICO, DA POR RESULTADO AL MENOS LA MEJORA DE LOS EFECTOS SECUNDARIOS PERJUDICIALES DE LA QUIMIOTERAPIA. EL TRATAMIENTO DE LAS CELULAS CANCEROSAS USANDO DPPE ILUSTRA ESPECIFICAMENTE LA INVENCION.
ES92901177T 1990-12-17 1991-12-16 Metodo de tratamiento mejorado para el cancer. Expired - Lifetime ES2063574T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62786390A 1990-12-17 1990-12-17
US71197591A 1991-06-07 1991-06-07

Publications (1)

Publication Number Publication Date
ES2063574T3 true ES2063574T3 (es) 1995-01-01

Family

ID=27090549

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92901177T Expired - Lifetime ES2063574T3 (es) 1990-12-17 1991-12-16 Metodo de tratamiento mejorado para el cancer.

Country Status (9)

Country Link
EP (1) EP0563127B1 (es)
JP (1) JP2706371B2 (es)
AT (1) ATE110966T1 (es)
AU (1) AU664978B2 (es)
CA (1) CA2098593C (es)
DE (1) DE69103908T2 (es)
DK (1) DK0563127T3 (es)
ES (1) ES2063574T3 (es)
WO (1) WO1992011035A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9303210D0 (en) * 1993-02-17 1993-03-31 Univ Manitoba Cancer treatment
AU749157B2 (en) * 1993-02-17 2002-06-20 University Of Manitoba Cancer treatment
US5432168A (en) * 1993-12-27 1995-07-11 University Of Manitoba Method of treatment of hormone-unresponsive metastatic prostate cancer
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US6506876B1 (en) * 1994-10-11 2003-01-14 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
US5863912A (en) * 1994-12-07 1999-01-26 Manitoba Cancer Treatment And Research Foundation Method of treatment of hormone-unresponsive metastiatic prostate cancer
AU2001257032A1 (en) * 2000-04-14 2001-10-30 University Of South Carolina Research Foundation Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
US6630454B2 (en) * 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
US20050119263A1 (en) * 2001-11-09 2005-06-02 Vincent Mark D. Treatment of breast cancer
CA2497180A1 (en) * 2002-09-04 2004-03-18 The University Of Manitoba Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist
EP3368024B1 (en) * 2015-10-27 2023-09-20 Akos Biosciences, Inc. Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1229604A (en) * 1984-02-14 1987-11-24 Lorne J. Brandes Aminoalkyl ethers of phenols as antiproliferative anticancer agents

Also Published As

Publication number Publication date
AU9058391A (en) 1992-07-22
DK0563127T3 (da) 1994-11-28
DE69103908T2 (de) 1995-01-05
JP2706371B2 (ja) 1998-01-28
EP0563127A1 (en) 1993-10-06
AU664978B2 (en) 1995-12-14
WO1992011035A1 (en) 1992-07-09
ATE110966T1 (de) 1994-09-15
EP0563127B1 (en) 1994-09-07
CA2098593A1 (en) 1992-06-18
CA2098593C (en) 1999-08-10
JPH06505710A (ja) 1994-06-30
DE69103908D1 (de) 1994-10-13

Similar Documents

Publication Publication Date Title
PA8588601A1 (es) Administracion combinada de una indolinona junto a un agente quimioterapeutico para el tratamiento de enfermedades de proliferacion celular
CR7140A (es) Antranilamidas con una cadena colateral de un heteroarylsulfonil, metodos para la produccion de los mismos, su uso como medicamento o agente diagnostico y preparaciones farmaceuticas contenidas en dichos compuestos
ES2249888T3 (es) Conjugados de paclitaxel solubles en agua, combinados con irradiacion para el tratamiento del cancer.
ES2063574T3 (es) Metodo de tratamiento mejorado para el cancer.
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
ES2190472T3 (es) Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno.
AR040722A1 (es) Formulaciones y formas de dosificacion para la administracion controlada de topiramato
MX9307555A (es) Derivados de paclitaxel y formulaciones farmaceuticas que los contienen.
ES2191192T3 (es) Tienopirimidinas.
ES2088388T3 (es) Composiciones de macrolido para el tratamiento de trastornos de movilidad gastrointestinal.
FI863664A0 (fi) Emulsionskompositioner foer dosering av i vatten svaorloesliga joniserbara hydrofoba laekemedel.
AR027091A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
ES2063011T3 (es) Agentes antibacteriales de quinolonas y naftiridinas que contienen un alfa-aminoacido en la cadena lateral del 7-sustituyente.
ES2096103T3 (es) Preparacion de comprimidos de resistencia incrementada.
ES2157975T3 (es) Soluciones farmaceuticas con solubilidad mejorada.
AR022860A1 (es) Derivados de camptotecina que poseen actividad antitumoral
DK1030670T3 (da) Anvendelse af vitamin D-derivater til forstærkning af virkningen af cytotoksiske midler
UA50719C2 (uk) Проліки для терапії пухлин і запальних захворювань
HN2004000232A (es) &#34; derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden.&#34;
ES2171933T3 (es) Derivados de androsteno.
SV2002000969A (es) Composicion parenteral reconstituible
AR022589A1 (es) UNA CÁPSULA QUE COMPRENDE UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL, UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL Y EL USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 563127

Country of ref document: ES